What Medendi does

Medendi (legal entity Lifetime s.r.l., founded circa 2019, headquartered in Modena, Italy) is a precision oncology diagnostics provider that connects cancer patients with advanced molecular testing and international oncology expertise. The company operates a direct-to-patient intake model in which a Scientific Committee of internationally affiliated oncologists, biologists, and researchers performs a free preliminary case evaluation within three days, then recommends and coordinates NGS genetic analysis (100-520 genes) and proteomic analysis (72 tumor marker proteins, exclusive in Europe per company claims). Core products include genetic analysis, proteomic analysis, hereditary risk assessment, experimental Minimal Residual Disease/recurrence-prevention analysis (in collaboration with Natera and C2i Genomics), and second-opinion referrals to centers including Memorial Sloan Kettering and Harvard Clinic. Diagnostic wet-lab work is executed through partner laboratories in the USA, Germany, and Italy rather than in Medendi-owned facilities.

Medendi's revenue model is professional services on a pay-as-you-go basis: the preliminary Scientific Committee evaluation is free, while the downstream diagnostic analyses are paid out-of-pocket by patients because these services are not reimbursed by the Italian National Health Service. Pricing is not publicly disclosed and is provided on a case-by-case quote basis. The company supplements its direct-to-patient channel with enterprise-style services to oncologists and private healthcare facilities, who receive diagnostic reports and therapeutic recommendations they can integrate into patient care. Marketing relies primarily on website content, organic social (Facebook, Twitter), and contact-form-driven lead capture.

The company is privately held with 1-10 employees and has raised 1.4 million euros in a February 2023 seed round (equity and debt) from a mix of strategic and individual investors. It maintains a wholly-owned US subsidiary, Medendi Inc., in New York City, and operates without a parent company. The leadership team consists of co-founders Giorgio Pasetto (Managing Director), Maurizio Scaltriti (Scientific Committee Coordinator; concurrently VP of Translational Medicine at AstraZeneca), and Gianmarco Molinari (CMO).

Name

Medendi

Legal name

Lifetime s.r.l.

Website

https://medendi.org

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Medendi is an Italy-based precision oncology diagnostics company that connects cancer patients with NGS genetic and proprietary proteomic tumor analysis, interpreted by an international Scientific Committee, on a direct-pay basis not reimbursed by the Italian NHS.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD)

Keywords

• Precision oncology diagnostics
• Molecular cancer diagnostics
• Genetic tumor analysis
• Proteomic tumor profiling
• Cancer second opinion

Headquarters

HQ city

Modena

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Diagnostic Services: Private diagnostic services including genetic and proteomic analysis for oncology patients. Services are paid by patients as they are not covered by the Italian National Health Service. Initial evaluation by the Scientific Committee is provided free of charge.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Medendi provides advanced molecular diagnostic services for cancer patients, including Next Generation Sequencing (NGS) genetic analysis of 100-520 tumor genes and exclusive-in-Europe proteomic analysis of 72 tumor protein markers. Results are interpreted by an international Scientific Committee of oncologists and researchers who deliver personalized therapeutic recommendations, including access to clinical trials, off-label drugs, and compassionate use therapies, along with hereditary risk and minimal residual disease (MRD) testing and second opinion consultations.

Product overview

Medendi provides advanced molecular diagnostics for precision oncology, offering genetic analysis (NGS sequencing of 100-520 genes) and exclusive proteomic analysis (72 protein tumor markers) as core diagnostic services. These are complemented by hereditary risk analysis, experimental MRD/recurrence prevention (in collaboration with Natera), and second opinion services. The company integrates with international laboratories and collaborates with leading oncological centers worldwide to deliver personalized diagnostic reports and therapeutic recommendations to patients and their treating oncologists.

Differentiator

Problem solved

Functional benefit

Products and services

• Analisi Genetica (Genetic Analysis) Next Generation Sequencing (NGS) analysis of 100 to 520 genes on tumor DNA/RNA to identify genetic alterations useful for therapeutic strategy, including clinical trials and compassionate use drugs. Results delivered as a report for both patient and treating oncologist.
• Analisi Proteomica (Proteomic Analysis) Proteomic analysis examining 72 tumor marker proteins to identify drug resistance or sensitivity patterns not detectable by genetic analysis alone, supporting oncologists in selecting optimal therapy. Can be used standalone or combined with genetic analysis.
• Analisi del Rischio Ereditario (Hereditary Risk Analysis) Germline DNA mutation analysis to evaluate hereditary cancer risk for family members of patients diagnosed with hereditary-related cancer pathologies.
• Prevenzione Recidive / MRD (Minimal Residual Disease / Recurrence Prevention)

Quantifiable outcome

• Identification of therapeutic options not previously considered by treating oncologists
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability1 record

Feature3 records

Partnerships

Six partnerships are on record, tiered core.

• NateracoreTechnology or IntegrationCollaboration for Minimal Residual Disease (MRD) analysis using circulating tumor DNA sequencing. Medendi implements this experimental protocol in Italy, creating a molecular fingerprint of the tumor from the most recent biopsy sample, followed by recurring liquid biopsy analyses.
• C2i GenomicscoreTechnology or IntegrationCollaboration for Minimal Residual Disease (MRD) analysis - experimental protocol for early detection of cancer recurrence through liquid biopsies and genetic analysis comparing circulating DNA with tumor molecular fingerprint.
• Specialized laboratories (USA, Germany, Italy)coreTechnology or IntegrationExternal specialized laboratories conduct the actual genetic and proteomic analyses. These are not Medendi facilities but certified laboratory partners.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerFor second opinion services, Medendi can refer cases to this center of excellence in the United States. Several Scientific Committee members are affiliated with MSKCC.
• Harvard CliniccoreStrategic or Co-development PartnerFor second opinion services, Medendi can refer cases to Harvard Clinic for highly qualified medical opinions.
• Various ecosystem partnerscoreOthersMedendi operates in synergy with companies of various sizes in multiple contexts: laboratories, AI and bioinformatics, biochemistry, logistics, clinics, and associations to deliver comprehensive oncology diagnostic services.

Scale indicators1 record

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Exact Sciences: Major molecular diagnostics company (Cologuard, Oncotype DX) expanding into oncology therapy selection and MRD. Overlaps with Medendi's cancer diagnostic positioning but operates as a broad public company with diversified product lines.
• NeoGenomics: Large US oncology-focused clinical laboratory offering comprehensive molecular testing including NGS, liquid biopsy, and pathology services. Competes with Medendi across most of its diagnostic menu but at substantially greater scale and with hospital system contracts.

Direct peers

• Tempus: AI-powered precision medicine company providing NGS tumor profiling (Tempus xT) and multi-omic analysis with clinical interpretation. Competes in the same patient and oncologist-facing precision oncology workflow that Medendi targets.
• Foundation Medicine: Roche-owned leader in comprehensive genomic profiling (NGS tumor testing) for oncology, offering assays such as FoundationOne CDx that are directly comparable to Medendi's genetic analysis service. Operates at much larger scale in the US/EU and is the primary reference point for NGS-based precision oncology.
• Caris Life Sciences: Offers MI Profile and other multi-omic tumor profiling (DNA, RNA, proteomics) with expert molecular tumor board interpretation — directly overlapping Medendi's combined NGS + proteomic + Scientific Committee value proposition.
• Natera: Provider of Signatera tumor-informed MRD testing — both a Medendi partner and a competitive peer offering similar ctDNA-based recurrence monitoring services to oncologists and patients.
• Guardant Health: Specializes in liquid biopsy and ctDNA-based MRD/recurrence monitoring (Guardant Reveal, Guardant360), directly competing with Medendi's Natera/C2i-based MRD offering for cancer recurrence surveillance.
• OncoDNA: Belgium-based precision oncology company offering NGS tumor profiling (OncoDNA, OncoKDM) combined with expert molecular tumor board interpretation for European patients — the closest European-headquartered competitor to Medendi.

Emerging players

• MolecularHealth: Germany-based precision oncology company offering molecular tumor profiling with integrated clinical decision support — comparable European-scale peer with a similar focus on therapy recommendation software layered on genomic data.
• Perthera: US precision oncology company combining multi-omic tumor profiling with an expert molecular tumor board to deliver ranked therapy and clinical trial recommendations — highly comparable to Medendi's NGS + Scientific Committee model at a similar scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Medendi2
• Facebookfacebook.com/bestcareinmedicalcare

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medendi